UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 29, 2021
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (203 ) 458-7100
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
||
|
|
|
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
From time to time, Quantum-Si Incorporated (the “Company”) presents and/or distributes slides and
presentations to the investment community to provide updates and summaries of its business. On September 29, 2021, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at https://ir.quantum-si.com. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
No.
|
Description
|
||
|
Corporate Presentation of Quantum-Si Incorporated dated September 29, 2021.
|
|||
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
QUANTUM-SI INCORPORATED
|
||
|
By:
|
/s/ John Stark
|
|
|
Name:
|
John Stark
|
|
|
Title:
|
Chief Executive Officer
|
|
|
Date: September 29, 2021
|
||
Exhibit 99.1
Quantum-SiInvestor Presentation Quantum-Si | INVESTOR UPDATE September 2021
Quantum-Si: Today’s Speakers Claudia DraytonChief Financial Officer John StarkChief Executive
Officer Dr Matthew DyerChief Business Officer
Disclaimer This presentation includes “forward-looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not
rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,”
“potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s
expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s
plans expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those
discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the
Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the Company’s recently-completed business combination,
which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in
the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its
products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and
supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s
future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following anticipated commercial launch; the Company’s estimates regarding
future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and
Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company
does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which
any such statement is based.
Driving the Forefront of Single Molecule Detection and Resolution Founded in 2013 and first to market
Single Molecule Protein Sequencing End to End Benchtop SystemExtensive IP portfolio: >500 Issued and/or Pending Patents*>$40B TAM: Expansion of Immune Understanding5+ Early Access Systems active with External SitesPublicly Traded on the
NASDAQ: QSI (June, 2021) raising $500M+ *Over 100 issued patents and 450 pending patent applications across 125 patent families
1990s The Next Transformation Anticipated in Life Sciences:Single Molecule Protein Sequencing
qPCR Sanger Microarrays Mass Spec ELISA Genomics Protein 2000s 2010s - Current Analog Gene and Transcript Resolution Birth of Digital DNA Sequencing Single Molecule, Benchtop Systems and Clinical Analog Protein and Peptide
Level Bench Top Single Molecule/Amino Acid Resolution Without legacy restrictions,QSi has the opportunity to compete successfully
Novel Therapies Current State of Treatment 90% OF APPROVED DRUGS TARGET A PROTEIN1 85% OF PROTEOME
UNDRUGGED2 Why is understanding the Proteome transformative?Proteins represent the clinical end point and building blocks of life What is there? How much is there? How has it been changed? 6 QUANTUM-SI Patient Care >100M
IMMUNOASSAY TEST/YEAR3 1 The Human Proteome Tissue Atlas – Druggable Proteome, 2015, The Human Protein Atlas Project 2 A Quest to Drug the Undruggable, June, Chemical & Engineering News, Volume 96, Issue 26, 2018 3 “NPS Focus”, Rainbow
makers, Royal Society of Chemistry (RSC), 2003, retrieved 29 December 2012
The Next Generation Protein Sequencing Solution Quantum-Si unique solution to enable absolute
quantification and resolution of the Proteome END-TO-ENDBENCHTOP SYSTEMDecentralization by enabling the scientific and clinical community 7 QUANTUM-SI SINGLE MOLECULE RESOLUTIONAbsolute measurement of unbiased biology providing novel
insights into variant and structure modifications TIME DOMAINSEQUENCING™ Novel sequencing method that provides interrogation at the amino acid level
End-to-End Protein Analysis Platform CARBONUniversal sample preparation for both protein and
DNA. PLATINUMScalable detection with single molecule sensitivity. CLOUDSecure data storage and analysis workflows. Sample Prep Sequencing Analysis
Mass Spec Digital DNA Sequencing Single Molecule DNA Sequencing Quantum-Si Quantitative Analysis
(Protein) ✅ ┈ ┈ ✅ Quantitative Analysis (DNA) ┈ ✅ ✅ ✅ Benchtop System ┈ ✅ ┈ ✅ Single Molecule ┈ ┈ ✅ ✅ Delivering on What We Believe the Market Demands
PROPRIETARY & CONFIDENTIAL Time Domain Sequencing™ provides amino acid resolution sequence of
single peptides across millions of wells in parallel RECOGNIZER F RECOGNIZER W RECOGNIZER Y RAW TRACE CUT F CUT W Example trace from sequencing the Human GLP1 protein
Time Domain Sequencing™ Validated by External Sites QUANTUM-SI CHIP LOADING 5+ global early access
partnersData shown was generated by ESPCI on an early access Platinum device
Leveraging Early Access for Application Development BARCODE RECOGNITION BARCODE REMOVAL BINDER
ADDITION CUTTER ADDITION PEPTIDE-BARCODE HYBRID COMPLEXES DUAL BARCODE AND PEPTIDE DYNAMIC RUNS Barcode development for sample multiplexing and future applications Collaboration with ESPCI and University of Wollongong DUAL
BARCODE RECOGNITION DUAL PEPTIDE RECOGNITION
Novel Biological Understanding:Next Frontier of Assessing Recurrence and Treatment Phosphorylated
Tyrosine Tyrosine Tyrosine phosphorylation is a marker for pathway activation, e.g. how cells responds to drugs, infection. Pathways Activation Our technology detects post-translational modifications like any other amino acid. We can
currently recognize phosphorylated tyrosine on chip and are working on other PTMs. Post-translational Modifications Estimated $10B/Year Therapy Market OpportunityEGFR/HER2 (Breast and Lung)
>132MMolecular Tests Performed Each Year in U.S Sequencing Clinical Testing >20,000Proteomics
InstrumentInstallations Quantitative Proteomics >16,000 Bench Top DNA Digital Sequencing Systems Potential Digital Disruption and Expansion of a $44B Market $31B (2020) 3% CAGR $5B (2020) 8% CAGR $8B (2020) 15%
CAGR Pharmaceutical and diagnostic development Basic Research, Discovery and Emerging Clinical Application Precision MedicineTargeted Therapies Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools
Kit 12th Edition.
Pathway for Growth and Customer Adoption DriveAdoption & Revenue ExpandUser Base $186M+
Revenue 2021 2025 DevelopNew Applications ✅ Initiated early access ✅ Scaled production/supply chain ✅ Building commercial organization Early Access DevelopKey Influencers Initial Launch Product Updates Portfolio
Expansion Status: Consumables Devices By 2025:> 5,000 units hardware>$45K annual pull through revenue/ deviceTarget gross margins > 70%
Company Core FocusesExpansion of Product Development and Commercial Organization2. Scale Product
Readiness and Supply ChainExpansion of Early Access Program Leading to Scaled Commercialization4. Accelerate Single Molecule Applications and Future Products Pioneering Next Generation Single Molecule Sequencing
